-
1 Comment
JW Pharmaceutical Corporation is currently in a long term uptrend where the price is trading 16.0% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
JW Pharmaceutical Corporation's total revenue rose by 27.0% to $145B since the same quarter in the previous year.
Its net income has increased by 70.1% to $-7B since the same quarter in the previous year.
Finally, its free cash flow fell by 65.1% to $9B since the same quarter in the previous year.
Based on the above factors, JW Pharmaceutical Corporation gets an overall score of 4/5.
| Industry | Drug Manufacturers-Specialty & Generic |
|---|---|
| Sector | Healthcare |
| ISIN | KR7001062009 |
| CurrencyCode | KRW |
| Exchange | KO |
| Dividend Yield | 0.7% |
|---|---|
| Beta | 0.26 |
| Target Price | None |
| PE Ratio | None |
| Market Cap | 522B |
JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 001067.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
